ARTICLE | Company News
FDA to review depression therapy from Takeda, Lundbeck
December 13, 2012 2:25 AM UTC
H. Lundbeck A/S (CSE:LUN) and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said FDA accepted for review an NDA for Brintellix vortioxetine to treat major depressive disorder (MDD). The PDUFA da...